The final authorisation is for the European Commission, which will take a position next week.
Remdesivir, an antiviral medicine that prevents the virus from replicating in the body, has just become, on the recommendation of the European Medicines Agency (EMA), the first drug indicated in Europe to treat patients with covid-19 in serious condition.
The indication of this drug is currently limited to adults and adolescents, from 12 years of age, who have pneumonia and who require supplemental oxygen intake.
The final authorisation for this use of remdesivir still depends on the decision of the European Commission, which will rule on this next week.
The use of this antiviral to combat covid-19 is supported, mainly, by the preliminary results of a study published on 22 May in the New England Journal of Medicine (NEJM), which concludes that this medicine can reduce the lethality of the virus by a proportion of between 7% and 12% to severe patients, and leads to earlier recovery of the patients. The EMA has also considered a recommendation from the Committee for Medicinal Products for Human Use (CHMP), with which it shares identical criteria in the clinical indication of remdesivir..
In Europe, the use of any specific coronavirus medicinal products had not yet been approved. Healthcare professionals have so far fought the disease using various drugs, such as dexamethasone or monoclonal antibodies.